论文部分内容阅读
酪氨酸激酶抑制剂(Tyrosine kinase inhibitors,TKIs)因服用方便,不良反应较少,已经逐渐取代传统治疗方法,成为慢性粒细胞白血病(CML)的一线治疗药物。伊马替尼是第一个上市的BCR-ABL蛋白激酶抑制剂,在靶向治疗慢性粒细胞白血病上取得了很大成功,但是随着伊马替尼的广泛应用和慢性粒细胞白血病的进展,部分患者发生了BCR-ABL激酶区的基因突变,对伊马替尼的敏感性下降从而发生耐
Tyrosine kinase inhibitors (TKIs) have become the first-line treatment for chronic myeloid leukemia (CML) because they are easy to take and have few adverse reactions. Imatinib, the first commercially available BCR-ABL protein kinase inhibitor, has achieved great success in targeting the treatment of chronic myeloid leukemia, but with the widespread use of imatinib and the development of chronic myelogenous leukemia , Some patients had a gene mutation in the BCR-ABL kinase region, the sensitivity of imatinib decreased occurrence of resistance